Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. Baird

Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report sent to investors on Tuesday morning, MarketBeat.com reports. The brokerage issued an outperform rating and a $31.00 price objective on the stock.

A number of other equities analysts have also recently weighed in on the company. Stifel Nicolaus upgraded Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price target for the company in a report on Monday, December 16th. William Blair assumed coverage on shares of Denali Therapeutics in a research note on Friday, January 3rd. They issued an “outperform” rating on the stock. Cantor Fitzgerald cut shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, October 7th. HC Wainwright cut their target price on Denali Therapeutics from $90.00 to $87.00 and set a “buy” rating on the stock in a research report on Tuesday. Finally, JPMorgan Chase & Co. decreased their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research note on Friday, October 11th. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $38.91.

Denali Therapeutics Trading Up 6.9 %

Shares of DNLI opened at $21.18 on Tuesday. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a market capitalization of $3.05 billion, a P/E ratio of -7.67 and a beta of 1.39. The firm has a 50-day moving average price of $24.34 and a 200 day moving average price of $24.88.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period last year, the business posted ($0.72) EPS. Equities research analysts predict that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. The trade was a 2.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now owns 235,807 shares in the company, valued at $6,529,495.83. This represents a 14.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 59,658 shares of company stock worth $1,667,943 over the last 90 days. 7.90% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

A number of large investors have recently bought and sold shares of DNLI. JPMorgan Chase & Co. raised its holdings in shares of Denali Therapeutics by 6.5% in the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock valued at $6,857,000 after buying an additional 14,324 shares during the last quarter. Principal Financial Group Inc. raised its stake in Denali Therapeutics by 13.8% during the 3rd quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock valued at $36,076,000 after acquiring an additional 149,939 shares during the last quarter. Franklin Resources Inc. lifted its position in Denali Therapeutics by 3.8% during the 3rd quarter. Franklin Resources Inc. now owns 80,041 shares of the company’s stock worth $2,148,000 after acquiring an additional 2,901 shares during the period. Barclays PLC grew its stake in shares of Denali Therapeutics by 101.4% in the 3rd quarter. Barclays PLC now owns 255,883 shares of the company’s stock valued at $7,454,000 after purchasing an additional 128,823 shares during the last quarter. Finally, Nomura Asset Management Co. Ltd. acquired a new position in shares of Denali Therapeutics in the third quarter valued at approximately $1,894,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.